The $400 price target for The Cigna Group (CI) has gained attention because it represents the most bullish outlook among Wall Street analysts. UBS analyst A.J. Rice raised the firm's target to $400 in May 2026, citing stronger-than-expected performance across managed care organizations and Cigna's positioning in the evolving healthcare landscape. With CI trading near $281, reaching $400 would require a gain of roughly 42% — a significant move that would push the stock well beyond its 52-week high near $315 and into territory not seen since 2022. For institutional and retail investors alike, the $400 level serves as both a psychological milestone and a test of whether Cigna's strategic transformation can command a higher valuation multiple.
The Cigna Group is one of the largest healthcare companies in the United States, operating through two primary segments: Cigna Healthcare, which provides medical, dental, and behavioral health insurance to approximately 16 million medical members domestically and 2 million internationally, and Evernorth Health Services, which encompasses pharmacy benefit management (PBM) through Express Scripts and specialty pharmacy services. The company rebranded from Cigna Corporation to The Cigna Group in February 2023, reflecting its broader portfolio strategy following the 2018 merger with Express Scripts. With a market capitalization near $74 billion and annual revenues exceeding $250 billion, CI ranks among the largest players in the healthcare plans industry.
CI shares have experienced significant volatility over the past 12 months, trading between a low of approximately $240 and a high near $315. The stock currently sits closer to the middle of that range, reflecting a market that remains uncertain about the regulatory outlook for PBMs and the pace of Cigna's specialty pharmacy growth. Despite this uncertainty, CI's valuation metrics present a compelling picture. The stock carries a forward P/E ratio of roughly 9.3 and a trailing P/E near 11.9 — levels that TD Cowen characterized as a "10-year valuation trough." With a dividend yield above 2% and an aggressive share buyback program, management has demonstrated confidence in the company's intrinsic value. The enterprise value-to-EBITDA (earnings before interest, taxes, depreciation, and amortization) ratio sits near 7.8, well below the sector median.
Several catalysts could support a sustained move higher. First, Cigna's specialty pharmacy business — particularly its $100 million investment in AI-powered specialty pharmacy infrastructure — represents a high-growth opportunity that Morgan Stanley described as "underappreciated." Second, the company's new rebate-free PBM model could position it ahead of potential regulatory reform, alleviating a major overhang on the stock. Third, Cigna's medical loss ratios have shown improvement, and TD Cowen's employer survey indicated fewer stop-loss clients expect to exceed coverage limits in 2025 compared to 2024, suggesting better underwriting profitability. Fourth, CI's conservative segment guidance, as noted by several analysts, leaves room for upside surprises. Finally, multiple expansion from the current depressed P/E toward historical averages near the mid-teens would alone account for a substantial portion of the move to $400.
The path to $400 is not without significant challenges. Regulatory scrutiny of PBM pricing practices remains the largest risk. Lawmakers from both parties have targeted the industry's role in drug pricing, and any legislative action that curtails PBM profitability would directly impact Cigna's Evernorth segment. Barclays and Deutsche Bank both downgraded CI in May 2026, with Deutsche Bank cutting to Hold at $302, specifically citing potential regulatory headwinds. Competitive pressure from UnitedHealth Group (UNH), Elevance Health (ELV), and CVS Health (CVS) remains intense, particularly as CVS integrates its own PBM with its retail pharmacy network. Additionally, rising specialty drug costs, including GLP-1 medications and gene therapies, continue to pressure industry margins. Insider selling activity has also drawn attention, with significant share sales by executives over recent quarters.
The analyst community remains predominantly bullish on CI, though targets vary widely. Of the roughly 25 analysts covering the stock, approximately 80% hold Buy or equivalent ratings, with none issuing Sell recommendations. The consensus price target sits near $341, implying roughly 21% upside from current levels. Beyond UBS at $400, Bernstein maintains a $381 target, Bank of America stands at $378, and Morgan Stanley holds at $361. On the more cautious side, Deutsche Bank's $302 target and Barclays' $304 reflect the regulatory uncertainty that keeps some investors on the sidelines. Notably, even the lowest analyst target of $297 remains above the current trading price, suggesting that the Street sees limited downside from these levels. The key question is whether CI can close the gap between the consensus near $341 and the bull case at $400.
From a technical perspective, CI faces well-defined zones of support and resistance. The $240–$260 area represents a significant support zone, having been tested multiple times and held during the October 2025 sell-off. The stock's 200-day moving average near $280 provides an additional layer of nearby support. On the upside, the $315–$335 region marks the 52-week high and serves as the first major resistance area that must be cleared before the stock can realistically target $400. A sustained break above $335 would represent a breakout from the current trading range and could attract momentum-driven buyers. The $400 level itself coincides with the stock's 2021–2022 trading range, adding technical significance to this round-number target. The path from current levels to $400 would likely require several stages: a recovery through $300, an eventual breakout above $335, and then a push toward the psychologically important $400 mark.
Traders monitoring CI and thousands of other stocks can leverage AI Daily Buy/Sell Signals from Tickeron. This tool uses artificial intelligence to continuously scan market data, technical patterns, and shifting conditions to generate actionable Buy, Sell, or Hold signals. By analyzing real-time price behavior and broader market trends, the AI helps traders identify emerging opportunities, manage existing positions, and stay ahead of trend changes without manually sifting through endless charts. For those watching whether CI can mount a sustained rally toward higher price targets, AI-driven signals can provide timely, data-backed guidance on entry and exit points as conditions evolve.
The question of whether The Cigna Group can reach $400 ultimately depends on three factors: regulatory clarity around PBM reform, successful execution of the specialty pharmacy growth strategy, and a broader market willingness to re-rate the stock away from its depressed valuation multiples. The bull case is grounded in real catalysts — CI's forward P/E under 10 leaves ample room for multiple expansion, the specialty pharmacy investment addresses a high-growth end market, and the new rebate-free PBM model could neutralize regulatory risk over time. However, the obstacles are equally real. The $400 target sits 42% above current levels, and the stock has struggled to sustain momentum above $315. Achieving the UBS target would likely require at least 12 to 18 months of consistent execution, favorable regulatory developments, and a market environment that rewards value-oriented healthcare names. Investors should monitor earnings trajectory, legislative developments affecting PBMs, specialty pharmacy revenue growth, and any signs of multiple expansion as indicators of whether the path to $400 is opening or closing.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CI has been loosely correlated with CVS. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if CI jumps, then CVS could also see price increases.